Logo image of SAGE

SAGE THERAPEUTICS INC (SAGE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SAGE - US78667J1088 - Common Stock

8.68 USD
-0.02 (-0.23%)
Last: 7/30/2025, 8:00:02 PM
8.685 USD
+0.01 (+0.06%)
After Hours: 7/30/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, SAGE scores 3 out of 10 in our fundamental rating. SAGE was compared to 535 industry peers in the Biotechnology industry. SAGE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, SAGE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SAGE had negative earnings in the past year.
In the past year SAGE has reported a negative cash flow from operations.
In the past 5 years SAGE reported 4 times negative net income.
SAGE had negative operating cash flow in 4 of the past 5 years.
SAGE Yearly Net Income VS EBIT VS OCF VS FCFSAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

1.2 Ratios

The Return On Assets of SAGE (-71.22%) is worse than 64.07% of its industry peers.
SAGE has a Return On Equity (-81.68%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -71.22%
ROE -81.68%
ROIC N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
SAGE Yearly ROA, ROE, ROICSAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

With a decent Gross Margin value of 45.16%, SAGE is doing good in the industry, outperforming 75.50% of the companies in the same industry.
SAGE's Gross Margin has declined in the last couple of years.
SAGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
SAGE Yearly Profit, Operating, Gross MarginsSAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SAGE has more shares outstanding
Compared to 5 years ago, SAGE has more shares outstanding
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SAGE Yearly Shares OutstandingSAGE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SAGE Yearly Total Debt VS Total AssetsSAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

SAGE has an Altman-Z score of -5.35. This is a bad value and indicates that SAGE is not financially healthy and even has some risk of bankruptcy.
SAGE has a Altman-Z score of -5.35. This is in the lower half of the industry: SAGE underperforms 61.52% of its industry peers.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.35
ROIC/WACCN/A
WACC11.13%
SAGE Yearly LT Debt VS Equity VS FCFSAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

SAGE has a Current Ratio of 9.16. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.16, SAGE is doing good in the industry, outperforming 75.32% of the companies in the same industry.
SAGE has a Quick Ratio of 9.16. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SAGE (9.16) is better than 75.50% of its industry peers.
Industry RankSector Rank
Current Ratio 9.16
Quick Ratio 9.16
SAGE Yearly Current Assets VS Current LiabilitesSAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

SAGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.60%, which is quite impressive.
The Revenue for SAGE has decreased by -27.58% in the past year. This is quite bad
Measured over the past years, SAGE shows a very strong growth in Revenue. The Revenue has been growing by 42.99% on average per year.
EPS 1Y (TTM)43.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.53%
Revenue 1Y (TTM)-27.58%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%265.84%

3.2 Future

SAGE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.71% yearly.
Based on estimates for the next years, SAGE will show a very strong growth in Revenue. The Revenue will grow by 40.01% on average per year.
EPS Next Y44.26%
EPS Next 2Y24.68%
EPS Next 3Y19.27%
EPS Next 5Y13.71%
Revenue Next Year93.34%
Revenue Next 2Y66.24%
Revenue Next 3Y54.03%
Revenue Next 5Y40.01%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SAGE Yearly Revenue VS EstimatesSAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SAGE Yearly EPS VS EstimatesSAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SAGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAGE Price Earnings VS Forward Price EarningsSAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAGE Per share dataSAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as SAGE's earnings are expected to grow with 19.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.68%
EPS Next 3Y19.27%

More info and screens

0

5. Dividend

5.1 Amount

SAGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGE THERAPEUTICS INC

NASDAQ:SAGE (7/30/2025, 8:00:02 PM)

After market: 8.685 +0.01 (+0.06%)

8.68

-0.02 (-0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-27 2025-10-27/bmo
Inst Owners80.99%
Inst Owner Change-99.21%
Ins Owners0.25%
Ins Owner Change-7.14%
Market Cap543.54M
Revenue(TTM)70.41M
Net Income(TTM)-301.19M
Analysts69.41
Price Target8.67 (-0.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.48%
Min EPS beat(2)0.49%
Max EPS beat(2)18.46%
EPS beat(4)3
Avg EPS beat(4)4.88%
Min EPS beat(4)-1.61%
Max EPS beat(4)18.46%
EPS beat(8)3
Avg EPS beat(8)-5.91%
EPS beat(12)4
Avg EPS beat(12)-4.23%
EPS beat(16)7
Avg EPS beat(16)-3.76%
Revenue beat(2)1
Avg Revenue beat(2)41.33%
Min Revenue beat(2)-2.5%
Max Revenue beat(2)85.16%
Revenue beat(4)2
Avg Revenue beat(4)19.35%
Min Revenue beat(4)-12.99%
Max Revenue beat(4)85.16%
Revenue beat(8)4
Avg Revenue beat(8)11.31%
Revenue beat(12)7
Avg Revenue beat(12)12.94%
Revenue beat(16)7
Avg Revenue beat(16)2.33%
PT rev (1m)-1.66%
PT rev (3m)5.63%
EPS NQ rev (1m)1.96%
EPS NQ rev (3m)-0.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.57%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)2.68%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.72
P/FCF N/A
P/OCF N/A
P/B 1.47
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-4.89
EYN/A
EPS(NY)-2.94
Fwd EYN/A
FCF(TTM)-4.62
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS1.12
BVpS5.89
TBVpS5.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -71.22%
ROE -81.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.16%
FCFM N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
F-Score3
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.16
Quick Ratio 9.16
Altman-Z -5.35
F-Score3
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)40.51%
Cap/Depr(5y)28.52%
Cap/Sales(3y)4.11%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.53%
EPS Next Y44.26%
EPS Next 2Y24.68%
EPS Next 3Y19.27%
EPS Next 5Y13.71%
Revenue 1Y (TTM)-27.58%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%265.84%
Revenue Next Year93.34%
Revenue Next 2Y66.24%
Revenue Next 3Y54.03%
Revenue Next 5Y40.01%
EBIT growth 1Y32.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.48%
EBIT Next 3Y19.55%
EBIT Next 5Y14.35%
FCF growth 1Y45.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.51%
OCF growth 3YN/A
OCF growth 5YN/A

SAGE THERAPEUTICS INC / SAGE FAQ

Can you provide the ChartMill fundamental rating for SAGE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SAGE.


Can you provide the valuation status for SAGE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to SAGE THERAPEUTICS INC (SAGE). This can be considered as Overvalued.


Can you provide the profitability details for SAGE THERAPEUTICS INC?

SAGE THERAPEUTICS INC (SAGE) has a profitability rating of 1 / 10.


How financially healthy is SAGE THERAPEUTICS INC?

The financial health rating of SAGE THERAPEUTICS INC (SAGE) is 6 / 10.